MNOV
vs
S&P 500
MNOV
S&P 500
Over the past 12 months, MNOV has underperformed S&P 500, delivering a return of -19% compared to the S&P 500's +12% growth.
Stocks Performance
MNOV vs S&P 500
Performance Gap
MNOV vs S&P 500
Performance By Year
MNOV vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
MediciNova Inc
Glance View
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company is headquartered in La Jolla, California and currently employs 11 full-time employees. The company went IPO on 2006-12-01. The firm is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. The company is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The firm's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.
